{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:51:51Z","timestamp":1785595911511,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00520-021-06757-x","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:03:55Z","timestamp":1642896235000},"page":"4081-4088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Shinagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-2950","authenticated-orcid":false,"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"key":"6757_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","volume":"11","author":"TY Cheng","year":"2016","unstructured":"Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME (2016) The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 11:1653\u20131671","journal-title":"J Thorac Oncol"},{"key":"6757_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","volume":"5","author":"C Zappa","year":"2016","unstructured":"Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5:288\u2013300","journal-title":"Transl Lung Cancer Res"},{"key":"6757_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","volume":"24","author":"H Akamatsu","year":"2019","unstructured":"Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y et al (2019) The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 24:731\u2013770","journal-title":"Int J Clin Oncol"},{"key":"6757_CR4","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055\u20132062","journal-title":"J Clin Oncol"},{"key":"6757_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924\u2013937","journal-title":"Lancet Oncol"},{"key":"6757_CR6","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040\u20132051","journal-title":"N Engl J Med"},{"key":"6757_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2165\/00003495-198937020-00005","volume":"37","author":"AJ Wagstaff","year":"1989","unstructured":"Wagstaff AJ, Ward A, Benfield P, Heel RC (1989) Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37:162\u2013190","journal-title":"Drugs"},{"key":"6757_CR8","doi-asserted-by":"publisher","first-page":"905091","DOI":"10.1155\/2013\/905091","volume":"2013","author":"I Cucinotto","year":"2013","unstructured":"Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N et al (2013) Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv 2013:905091","journal-title":"J Drug Deliv"},{"key":"6757_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/JTO.0b013e3181d5e39e","volume":"5","author":"MA Socinski","year":"2010","unstructured":"Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV et al (2010) A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 5:852\u2013861","journal-title":"J Thorac Oncol"},{"key":"6757_CR10","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"6757_CR11","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-018-4869-5","volume":"18","author":"Z Ghoreishi","year":"2018","unstructured":"Ghoreishi Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, Goodman KA, Esfahani A (2018) Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer 18:958","journal-title":"BMC Cancer"},{"key":"6757_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/jns.12271","volume":"23","author":"J Robertson","year":"2018","unstructured":"Robertson J, Raizer J, Hodges JS, Gradishar W, Allen JA (2018) Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients. J Peripher Nerv Syst 23:129\u2013133","journal-title":"J Peripher Nerv Syst"},{"key":"6757_CR13","doi-asserted-by":"publisher","first-page":"e784","DOI":"10.1634\/theoncologist.2018-0418","volume":"24","author":"L S\u00e1nchez-Barroso","year":"2019","unstructured":"S\u00e1nchez-Barroso L, Apellaniz-Ruiz M, Guti\u00e9rrez-Guti\u00e9rrez G, Santos M, Rold\u00e1n-Romero JM, Curras M et al (2019) Concomitant medications and risk of chemotherapy-induced peripheral neuropathy. Oncologist 24:e784\u2013e792","journal-title":"Oncologist"},{"key":"6757_CR14","doi-asserted-by":"publisher","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K et al (2020) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","DOI":"10.1007\/s10147-020-01818-3"},{"key":"6757_CR15","volume-title":"package insert on the internet","author":"Abraxane\u00ae (nanoparticle albumin-bound paclitaxel)","year":"2014","unstructured":"Abraxane\u00ae (nanoparticle albumin-bound paclitaxel) (2014) package insert on the internet. Taiho pharmaceutical Co., Tokyo http:\/\/www.info.pmda.go.jp\/downfiles\/ph\/PDF\/400107_4240409D1023_1_12.pdf. accessed Apr 19, 2019"},{"key":"6757_CR16","unstructured":"Abraxane\u00ae (nanoparticle albumin-bound paclitaxel) (2020) [HIGHLIGHTS OF PRESCRIBING INFORMATION]. Abraxis BioScience. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021660s047lbl.pdf. accessed Apr 19, 2021"},{"key":"6757_CR17","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1200\/JCO.1998.16.5.1811","volume":"16","author":"AP Venook","year":"1998","unstructured":"Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G et al (1998) Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16:1811\u20131819","journal-title":"J Clin Oncol"},{"key":"6757_CR18","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1200\/JCO.1994.12.8.1621","volume":"12","author":"WH Wilson","year":"1994","unstructured":"Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A et al (1994) Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I\/II trial of 96-hour infusion. J Clin Oncol 12:1621\u20131629","journal-title":"J Clin Oncol"},{"key":"6757_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/oxfordjournals.annonc.a059287","volume":"6","author":"MT Huizing","year":"1995","unstructured":"Huizing MT, Vermorken JB, Rosing H, ten Bokkel Huinink WW, Mandjes I, Pinedo HM et al (1995) Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 6:699\u2013704","journal-title":"Ann Oncol"},{"key":"6757_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2125.2007.02956.x","volume":"64","author":"M Joerger","year":"2007","unstructured":"Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H et al (2007) Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 64:622\u2013633","journal-title":"Br J Clin Pharmacol"},{"key":"6757_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.lungcan.2013.02.020","volume":"81","author":"M Satouchi","year":"2013","unstructured":"Satouchi M, Okamoto I, Sakai H, Yamamoto N, Ichinose Y, Ohmatsu H et al (2013) Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 81:97\u2013101","journal-title":"Lung Cancer"},{"key":"6757_CR22","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703","journal-title":"N Engl J Med"},{"key":"6757_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","volume":"77","author":"H Ueno","year":"2016","unstructured":"Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y et al (2016) Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77:595\u2013603","journal-title":"Cancer Chemother Pharmacol"},{"key":"6757_CR24","doi-asserted-by":"publisher","unstructured":"Saito Y, Takekuma Y, Kobayashi M, Komatsu Y, Sugawara M (2020) Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-020-05842-x","DOI":"10.1007\/s00520-020-05842-x"},{"key":"6757_CR25","first-page":"113","volume":"11","author":"TK Bergmann","year":"2011","unstructured":"Bergmann TK, Brasch-Andersen C, Gr\u00e9en H, Mirza M, Pedersen RS, Nielsen F et al (2011) Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharm J 11:113\u2013120","journal-title":"Pharm J"},{"key":"6757_CR26","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdt018","volume":"24","author":"DL Hertz","year":"2013","unstructured":"Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL et al (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24:1472\u20131478","journal-title":"Ann Oncol"},{"key":"6757_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597\u2013607","journal-title":"Pharmacogenetics"},{"key":"6757_CR28","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.2147\/OTT.S106574","volume":"9","author":"T Kus","year":"2016","unstructured":"Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S et al (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Oncol Targets Ther 9:5073\u20135080","journal-title":"Oncol Targets Ther"},{"key":"6757_CR29","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00280-017-3314-9","volume":"79","author":"Y Tanabe","year":"2017","unstructured":"Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D et al (2017) Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol 79:1179\u20131186","journal-title":"Cancer Chemother Pharmacol"},{"key":"6757_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/cas.12647","volume":"106","author":"H Kenmotsu","year":"2015","unstructured":"Kenmotsu H, Tanigawara Y (2015) Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci 106:497\u2013504","journal-title":"Cancer Sci"},{"key":"6757_CR31","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s00520-019-04773-6","volume":"27","author":"P Chambers","year":"2019","unstructured":"Chambers P, Jani Y, Wei L, Kipps E, Forster MD, Wong ICK (2019) Patient factors and their impact on neutropenic events: a systematic review and meta-analysis. Support Care Cancer 27:2413\u20132424","journal-title":"Support Care Cancer"},{"key":"6757_CR32","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1200\/JCO.2016.67.2899","volume":"34","author":"A Agiro","year":"2016","unstructured":"Agiro A, Ma Q, Acheson AK, Wu SJ, Patt DA, Barron JJ et al (2016) Risk of neutropenia-related hospitalization in patients who received colony-stimulating factors with chemotherapy for breast cancer. J Clin Oncol 34:3872\u20133879","journal-title":"J Clin Oncol"},{"key":"6757_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2020.01.004","volume":"141","author":"X Cao","year":"2020","unstructured":"Cao X, Ganti AK, Stinchcombe T, Wong ML, Ho JC, Shen C et al (2020) Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. Lung Cancer 141:14\u201320","journal-title":"Lung Cancer"},{"key":"6757_CR34","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cncr.25691","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917\u20131927","journal-title":"Cancer"},{"key":"6757_CR35","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1080\/1042819031000119262","volume":"44","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M (2003) Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 44:2069\u20132076","journal-title":"Leuk Lymphoma"},{"key":"6757_CR36","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ygyno.2012.03.015","volume":"125","author":"RA Laskey","year":"2012","unstructured":"Laskey RA, Poniewierski MS, Lopez MA, Hanna RK, Secord AA, Gehrig PA et al (2012) Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol 125:625\u2013630","journal-title":"Gynecol Oncol"},{"key":"6757_CR37","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/bjc.2015.122","volume":"112","author":"W Ichikawa","year":"2015","unstructured":"Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H et al (2015) An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. Br J Cancer 112:1709\u20131716","journal-title":"Br J Cancer"},{"key":"6757_CR38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10147-014-0746-7","volume":"20","author":"K Shigeta","year":"2015","unstructured":"Shigeta K, Kosaka T, Yazawa S, Yasumizu Y, Mizuno R, Nagata H et al (2015) Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer. Int J Clin Oncol 20:605\u2013612","journal-title":"Int J Clin Oncol"},{"key":"6757_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00520-012-1580-y","volume":"21","author":"N Jiang","year":"2013","unstructured":"Jiang N, Chen XC, Zhao Y (2013) Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer. Support Care Cancer 21:785\u2013791","journal-title":"Support Care Cancer"},{"key":"6757_CR40","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00520-006-0034-9","volume":"14","author":"M Schwenkglenks","year":"2006","unstructured":"Schwenkglenks M, Jackisch C, Constenla M, Kerger JN, Paridaens R, Auerbach L et al (2006) Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 14:901\u2013909","journal-title":"Support Care Cancer"},{"key":"6757_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","volume":"19","author":"M Schwenkglenks","year":"2011","unstructured":"Schwenkglenks M, Pettengell R, Jackisch C, Paridaens R, Constenla M, Bosly A et al (2011) Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Support Care Cancer 19:483\u2013490","journal-title":"Support Care Cancer"},{"key":"6757_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","volume":"144","author":"R Pettengell","year":"2009","unstructured":"Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R et al (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 144:677\u2013685","journal-title":"Br J Haematol"},{"key":"6757_CR43","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clgc.2016.05.012","volume":"15","author":"Y Hirasawa","year":"2017","unstructured":"Hirasawa Y, Nakashima J, Sugihara T, Takizawa I, Gondo T, Nakagami Y et al (2017) Development of a nomogram for predicting severe neutropenia associated with docetaxel-based chemotherapy in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 15:176\u2013181","journal-title":"Clin Genitourin Cancer"},{"key":"6757_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/COC.0b013e318165c01d","volume":"31","author":"G Dranitsaris","year":"2008","unstructured":"Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D et al (2008) Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol 31:369\u2013374","journal-title":"Am J Clin Oncol"},{"key":"6757_CR45","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"key":"6757_CR46","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785\u2013792","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06757-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T19:15:08Z","timestamp":1666898108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06757-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6757"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06757-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,23]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}